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The nervous system is enormously complex, yet the
number of cues that control axonal growth is sur-
prisingly meager. Posttranslational modifications
amplify diversity, but the degree to which they are
employed is unclear. Here, we show that Furin and
SKI-1 combine with autocatalytic cleavage and a
disulfide bridge to generate four membrane-bound
and three soluble forms of the repulsive guidance
molecule (RGMa). We provide in vivo evidence that
these proprotein convertases are involved in axonal
growth and that RGMa cleavage is essential for Neo-
genin-mediated outgrowth inhibition. Surprisingly,
despite no sequence homology, N- and C-RGMa
fragments bound the same Fibronectin-like domains
in Neogenin and blocked outgrowth. This represents
an example in which unrelated fragments from one
molecule inhibit outgrowth through a single receptor
domain. RGMa is a tethered membrane-bound
molecule, and proteolytic processing amplifies
RGMa diversity by creating soluble versions with
long-range effects as well.
INTRODUCTION
Axonal outgrowth is precisely orchestrated during development
to ensure correct connectivity within the nervous system (Tess-
ier-Lavigne and Goodman, 1996). Surprisingly, however, there
are a relatively limited number of known guidance proteins
(Thanos and Mey, 2001). Posttranslational modification is one
strategy to generate multiple activities from a single protein. In
theory, complex proteolytic processing with alternate use of
multiple specific cleavage sites could dramatically increase
diversity (Zisman et al., 2007). Semaphorins, which have several
cleavage sites, are one example (Adams et al., 1997), but the
extent to which this strategy is utilized and the effects on activity,
receptor specificity, and/or short (membrane-bound) versus
long-range (soluble) effects are largely unknown.
The GPI-anchored protein RGMa is key to the development of
various projections within the CNS and is thought to act solely asDevelopma membrane-bound protein (Monnier et al., 2002). Its activity is
similar to that of the ephrins, as it inhibits retinal ganglion cell
(RGC) outgrowth (Monnier et al., 2002). RGMa acts through the
transmembrane receptor Neogenin, which is expressed in
a high-temporal low-nasal gradient in RGC axons (Rajagopalan
et al., 2004). In vitro, temporal axons that express Neogenin
avoid RGMa-expressing cells, whereas Neogenin-deficient
nasal axons are not affected by RGMa (Rajagopalan et al.,
2004). In vivo, perturbation of the RGMa gradient in the optic
tectum causes pathfinding mistakes for temporal fibers (Matsu-
naga et al., 2006). Thus, Neogenin and RGMa provide positional
information for retinal axons invading the tectum. Besides its
contribution to the establishment of the neuronal architecture,
RGMa is a major impediment to neuronal regeneration. Strik-
ingly, antibodies that block RGMa activity promote functional
recovery after spinal cord injury (Hata et al., 2006). Thus, to opti-
mize therapeutics that promote axonal regeneration it is critical
to understand how RGMa contributes to the nonpermissive
regenerative milieu of the CNS.
Current understanding of RGMa processing derives from
studies in transfected COS-7 cells, but the in vivo cleavage
pattern remains uncharacterized (Tassew et al., 2009). Here we
show that RGMa processing is far more complex than originally
thought. Thus, alternative cleavage by the Proprotein Conver-
tases Subtilisin Kexin Isozyme-1 (SKI-1) and Furin generates
multiple membrane-bound and soluble forms, and the resulting
peptides have dramatically different potencies, including
released forms. In stark contrast to nonmembrane-bound eph-
rins that do not influence axonal outgrowth, we show that soluble
forms of RGMa are inhibitory. Unexpectedly, distinct RGMa
products with no sequence homology operate through the
same Fibronectin III (3-4) domains in Neogenin. As RGMs are
implicated in many human disorders (Papanikolaou et al.,
2004; Nohra et al., 2010), the discovery of multiple derivatives
is expected to have important implications for therapeutic
targeting.RESULTS
Complex In Vivo RGMa Processing
We performed western blotting on membrane preparations
under reducing (+DTT) and nonreducing conditions (-DTT) to
allow analysis of the RGMa disulfide bridge. As reported,ental Cell 22, 391–402, February 14, 2012 ª2012 Elsevier Inc. 391
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Figure 1. Analysis of RGMa Processing
(A) Schematic representation of the seven RGMa peptides identified in our
analysis. In membranes under reducing (+DTT) or nonreducing (-DTT) condi-
tions, an anti-C-RGMa revealed four RGMa fragments. In cell supernatant
(-DTT), an anti-N-RGMa revealed that three RGMa fragments are released.
Molecular weights are indicated on the right; UG unglycosylated. Black arrow
head indicates autocatalytic cleavage site, black arrow represents known
shedding cleavage site. Red arrows indicate calculated cleavage sites cor-
responding to soluble isoforms.
(B) Western blots with an anti-C-RGMa on membranes from RGMa-trans-
fected COS-7 cells, the developing chick brain, and RGMa-transfected
HEK293 cells. Analysis was performed under nonreducing conditions (-DTT) to
preserve the disulfide bridge or under reducing conditions (+DTT). Under
nonreducing conditions, one band is visible in COS-7 cells (60 kDa), whereas
three bands (33, 37, and 60 kDa) are visible in chick brain and HEK293. Under
reducing conditions two bands (33 and 60 kDa) are visible in membranes. This
revealed four membrane-bound RGMa proteins in chick brain (represented in
A; see also Figure S1).
(C) Western blots (-DTT) performed with an anti-N-RGMa on brain matrix
extracts (urea 3M) revealed a 30 kDa band. In supernatants from RGMa-trans-
fected HEK cells, two bands at 60 and 30 kDa are apparent. PNGaseF (NGase)
treatment to remove N-glycosylations (UG) reduced the 60 kDa to a 45 kDa
band and the 30 kDa to 22 and 18 KDa bands (arrow heads) (represented in A).
(D and E) Temporal retinal explants cultured on supernatants from cells
transfected with control (Mock, D) or RGMa (E). Bar, 200 mm.
(F) Average axonal length was significantly shorter on supernatants from
RGMa-transfected cells versus control (Mock; **p < 0.0005). Data are
average ± SEM from three independent experiments.
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392 Developmental Cell 22, 391–402, February 14, 2012 ª2012 Elsevmembranes from COS-7 cells transfected with RGMa contained
a single 60 kDa protein, which DTT reduced to a 33 kDa
C-terminal RGMa fragment (‘‘C-RGMa’’) due to the presence
of an autocatalytic cleavage site at residue 150 (Figures 1A
and 1B, lanes 1 and 2; Tassew et al., 2009). Some of the
60 kDa band remained even after DTT treatment (Figure 1B,
lane 2) suggesting thatmembranes contain both cleaved and un-
cleaved full-length RGMa (Figure 1A, CFL-RGMa and U-RGMa,
respectively; Tassew et al., 2009). Whereas the C-terminal anti-
body only detected full-length 60 kDa protein on nonreduced
COS-7 membranes (Figure 1B, lane 1), this protein plus the
33 kDa C-RGMa fragment and an unexpected 37 kDa species
(‘‘RGMa37’’) were observed on nonreducedmembrane prepara-
tions from chick brain (Figure 1B, lane 3). Thus, in brain C-RGMa
is present on membranes both as a linked heterodimer with
N-RGMa (33 kDa+22 kDa), and on its own (33 kDa alone) (Fig-
ure 1B). The RGMa37 fragment disappeared after treatment
with DTT (Figure 1B, lane 4) and must, therefore, arise from a
second in vivo cleavage site located within the N-terminal part
of RGMa, and consists of the 33 kDa C-RGMa fragment
disulfide linked to a calculated 4 kDa N-RGMa fragment (Fig-
ure 1A). In summary, western blots with the C-terminal antibody
suggest the presence of four distinct membrane-anchored
RGMa proteins in vivo: CFL-RGMa (60 kDa), U-RGMa (60 kDa),
C-RGMa (33 kDa), and RGMa37 (37 kDa).
RGMa Is Processed into Soluble Proteins that Inhibit
Axonal Growth
To further test and extend these conclusions we sought to iden-
tify cell lines which, unlike COS-7, recapitulate themore complex
cleavage pattern seen in chick brain. Strikingly, western blotting
with the C-terminal antibody on membranes from HEK293, and
SH-SY5Y cells, but not COS-7 or DF1 cells, transfected with
RGMa showed a pattern similar to the one observed in brain (Fig-
ure 1B, lanes 5 and 6; Figure S1 available online). While RGMa
processing in HEK293 or SH-SY5Y cells did not seem as efficient
as in the brain, these model cell lines could be used to study
this process. The presence of two cleavage sites within the
N-terminal domain should lead to the release of two small
N-terminal fragments (Figure 1A, N-RGMa and NN-RGMa,
respectively). Thus, we sought to identify these fragments in
chick brain matrix extracts using N-terminal anti-RGMa anti-
bodies. Surprisingly, we could only reveal the presence of one
30 kDa band that was bigger than any of the expected N-terminal
fragments (Figure 1C). We extended this study to the medium of
RGMa-transfected HEK293 cells and detected two RGMa
proteins with apparent molecular masses of 60 and 30 kDa (Fig-
ure 1C, lane 1). The 60 kDa has been described before and
results from RGMa shedding from the membrane (RGMaD) by
a phospholipase (Hata et al., 2006) and may not be biologically
relevant as it is not seen in brain matrices. The 30 kDa band
was broad, so we surmised that it represented a glycosylated
N-terminal fragment. To test this hypothesis, we removed N-
glycosylations using PNGaseF and assessed its resultingmolec-
ular mass bywestern blot. Once unglycosylated (UG), the 60 kDa
was reduced to one 45 kDa band whereas the 30 kDa resulted
in 2 bands (18 and 22 kDa) that correspond to N-RGMa and
NN-RGMa (Figure 1C). Thus, RGMa processing in HEK leads
to the secretion of three soluble fragments: N-RGMa (30 kDa;ier Inc.
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Figure 2. Furin and SKI-1 Process RGMa and Are Involved in Path-
finding
(A) RGMa-expressing cells were treated with the protease inhibitors AEBSF or
RVKR, or DMSO (control) and membranes blotted. AEBSF and RVKR both
strongly reduced RGMa cleavages, shown by the reduction of the 33 and
37 kDa bands (asterisks) (see also Figures S2A and S2B).
(B) RGMa-expressing cells were treated with RVKR or RRLL protease inhibi-
tors or DMSO (control). Blots on membranes under reducing (+DTT) and
nonreducing (-DTT) conditions show that RVKR inhibits the two cleavage
events (asterisks), whereas the SKI-1 inhibitor RRLL inhibited generation of the
33 kDa protein only (asterisk). In the presence of DTT a 33 kDa band appears
indicating that autocatalytic cleavage is not sensitive to treatments.
(C) RGMa was cotransfected with R134E or empty plasmid (control). In
membranes, R134E strongly reduced formation of the 33 kDa protein
(asterisk), confirming that it is the result of SKI-1 activity.
(D) RGMa was cotransfected with ppFurin or empty plasmid (Ctrl). ppFurin
strongly reduced formation of the 37 kDa fragment, confirming that it results
from Furin activity (see also Figure S2).
(E) RGMa-expressing cells were treated with DMSO (control) or RVKR and
supernatants were blotted with anti-N-RGMa. RVKR suppressed release of
N-terminal proteins (asterisk).
(F–H) In situ analysis demonstrated that Furin and SKI-1 are expressed in the
tectum in RGMa-expressing radial glial cells (arrows). Controls (sense) did not
show any staining (H).
(I) Injection of empty virus did not induce axonal phenotypes and all axons
established terminal arbors within the terminal zone (TZ).
(J) Ectopic expression of a SKI-1 pro-form (R134E) induced axonal pheno-
types with numerous fibers establishing arbors outside the TZ.
(K) Ectopic expression of ppFurin to neutralize Furin induced axonal
phenotypes with numerous fibers establishing arbors outside the TZ (arrow-
heads).
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Developm22 kDa unglycosylated [UG]), NN-RGMa (30 kDa; 18 kDa [UG])
and RGMaD (60 kDa; 45 kDa [UG]).
To address the role of RGMa soluble proteins on growing
axons, we cultured retinal explants in the presence of superna-
tant from cells that were either Mock transfected or transfected
with full-length RGMa (Figures 1D–1F). Interestingly, cells grown
on supernatant from RGMa-transfected HEK293 cells showed
markedly reduced axonal growth (41.3 ± 6 mm) relative to those
grown on media from Mock-transfected cells (131 ± 2.1 mm).
Thus, RGMa-expressing cells release factors that hamper
axonal growth.
SKI-1 and Furin Process RGMa
The identification of 33 and 37 kDa species in membranes could
be explained by two cleavage events, one within the N-terminal
domain and one next to the autocatalytic site, respectively (Fig-
ure 1A). To identify the enzyme(s) that cleave(s) RGMa we
treated cells with protease inhibitors. Of the many inhibitors
tested, only AEBSF, a membrane permeable inhibitor for serine
proteases, showed a significant reduction of RGMa cleavage
(Figure 2A; Figure S2A). Interestingly, another non-membrane-
permeable serine protease inhibitor (Aprotinin) did not show
any reduction in cleavage. Because this indicates that RGMa is
cleaved on its way toward the cell surface, we tested two inhib-
itors of transport from the endoplasmic reticulum (ER) to the
Golgi (Seidah et al., 1999). Both Golgicide A and Brefeldin A
did not have any effect on RGMa processing, indicating that it
is cleaved within the ER (Figure S2B). This behavior corresponds
to the one observed with Proprotein Convertases (PCs); hence,
we tested the cell-permeable RVKR peptide, a broad inhibitor
for PCs (Seidah and Chre´tien, 1999). Membranes were analyzed
by western blotting under nonreducing conditions, which
showed that both the 33 and the 37 kDa bands, were completely
abolished by RVKR treatments (Figure 2A). PCs normally require
two arginines for cleavage; however, we could not identify any
PC consensus sequence next to the autocatalytic site. Thus,
we suspected that another PC that does not require arginines
to induce cleavage was involved in RGMa processing. Because
Subtilisin Kexin Isoenzyme-1 (SKI-1) does not require a basic
residue at the cleavage site (Pasquato et al., 2006), we tested
whether specific SKI-1 inhibition with the cell-permeable RRLL
peptide inhibitor could prevent RGMa processing. Indeed, this
peptide completely abolished formation of the 33 kDa band
but not the 37 kDa suggesting that SKI-1 mediates generation
of the former protein (Figure 2B). In all cases, the presence of
DTT resulted in the formation of the 33 kDa band indicating
that treatments with these inhibitors did not suppress the auto-
catalytic cleavage event (Figure 2B).
To confirm that SKI-1 is involved in RGMa processing, we
expressed a prosegment inhibitor of this enzyme (R134E; Fig-
ure 2C; Pullikotil et al., 2004) together with RGMa. Here again,
SKI-1 inhibition dramatically reduced formation of the 33 kDa
band (Figure 2C). Next, we tested whether Furin processes
RGMa by using a Furin-prosegment inhibitor construct that
specifically prevents Furin cleavage (ppFurin; Zhong et al.,
1999). Here, the formation of the 37 kDa species was blocked
suggesting the involvement of Furin (Figure 2D). This was
confirmed by the fact that soluble RGMa formed a 37 kDa
band when treated by purified Furin (Figure S2). Finally, toental Cell 22, 391–402, February 14, 2012 ª2012 Elsevier Inc. 393
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peptides, we studied cell supernatants after treatment with
RVKR. As expected, the 60 kDa band but not the 30 kDa band
was released by RGMa-expressing cells (Figure 2E).
In summary, RGMa processing is far more complex than
previously appreciated; thus, autocatalytic cleavage and
proteolytic cleavage by SKI-1 and Furin generate seven distinct
species (Figure 1A). Furthermore, RGMa is N-glycosylated,
adding to the complexity of its posttranslational modifications
(Figure 1).
SKI-1 and Furin Are Involved in Axonal Guidance
Although Furin activates Semaphorins (Adams et al., 1997), its
in vivo function on growing axons remains unclear. We therefore
investigated the role of Furin and SKI-1 on visual paths. First, we
studied expression of these proteins using in situ hybridization
in the optic tectum. Our data revealed that both proteins are
expressed in RGMa-expressing radial glia cells (Figures 2F–
2H), which fits the idea that they may be involved in retino-tectal
pathfinding. Next, we performed ectopic-expression of SKI-1-
(R134E) and Furin-inhibitors (ppFurin) in developing chicks
(Figures 2I–2K) using the RCAS viral vector and studied retinal
tracts from the eye to the optic tectum using DiI tracing. As
expected, both SKI-1 and Furin inhibitions induced axonal
phenotypes within the tectum. We observed that many fibers
failed to target the terminal zone and arborized randomly within
the tectum, when compared to controls (Figures 2I–2K). ppFurin
induced aberrant paths in all embryos (n = 8) and 70% (7 of 10) of
the R134E embryos but none of the controls (n = 6) displayed
phenotypes. Furin and SKI-1 may regulate the activity of other
guidance molecule. Indeed, Furin activates Semaphorins, which
are critical for the growth of many axons (Adams et al., 1997).
While these experiments do not directly show that RGMa
cleavage by Furin and SKI-1 regulates axonal paths, they are
consistent with that model and provide in vivo evidence that
these enzymes play a critical role in the regulation of axonal
growth.
RGMa Cleavage Is Required for Neogenin Binding
and Outgrowth Inhibition
The above insights raise important questions regarding the bio-
logical relevance of each of the multiple cleavage sites and the
relative activity of each resulting peptide. First we examined
whether RGMa cleavage is required for interaction with Neoge-
nin. For this, we generated mutations next to the auto-catalytic
cleavage site (D149A, H151A) and showed that these mutations
altered all cleavage events (Figure 3B). These mutations did not
change RGMa processing toward the cell surface (Figure S3).
We then performed an ELISA assay in which Neogenin-AP inter-
acts with membranes from COS-7 cells transfected with RGMa
constructs (Figures 3A–3C; Figures S3A–S3C). In agreement
with previous observations, wt RGMa interacted with Neoge-
nin-AP (Rajagopalan et al., 2004), however, the two RGMa
mutants did not interact with Neogenin (Figures 3B and 3C).
Binding of membrane-bound RGMa to Neogenin is believed to
be necessary for RGMa to exert its inhibition on axonal growth
(Rajagopalan et al., 2004). To address this issue, we tested
whether the RGMa mutants (D149A, H151A) inhibit axonal
growth of Neogenin-expressing temporal axons. As controls,394 Developmental Cell 22, 391–402, February 14, 2012 ª2012 Elsevwe cultured nasal axons that express lower amounts of Neoge-
nin. As expected, temporal explants grown on wt RGMa
membranes extended shorter axons (197.6 ± 7.5 mm) when
compared to the otherwise long axons on Mock membranes
(407.9 ± 16.7 mm) (Figures 3D and 3E). Outgrowth on U-RGMa
mutants was 70.8% (335.7 ± 11.7 mm; p < 0.0001; D149A) and
82.2% longer (360 ± 6.1 mm; p < 0.0001; H151A) than on wt
RGMa (Figures 3D and 3E). Because they express lower
amounts of Neogenin, the reduction in length for nasal axons
on wtRGMa versus control was lesser than the one observed
with temporal axons (Figure 3E).
To confirm that catalytic cleavage is essential for Neogenin-
mediated inhibition, we studied neurite growth on Neogenin-
expressing NIE-115 cells (Endo and Yamashita, 2009). RGMa-
containing membranes inhibited NIE-115 neurite extension
compared to control Mock-transfected membranes (Figures 3F
and 3G). This effect was Neogenin-dependent as it was sup-
pressed when cells were treated with a Neogenin shRNA (Fig-
ure 3G; Figure S3), but not with control shRNA (Figure 3F and
3G). Here again, noncleavable mutants did not inhibit growth
(Figures 3F and 3G).
We next examined the effect of RGMa cleavage on axonal
pathfinding and performed ectopic expression of wt RGMa
andU-RGMa (H151A). As expected, tectal infection with a vector
that expressed wt RGMa induced strong pathfinding mistakes
(Figure 3H). In 100% of the embryos (13 of 13), we observed
that axons established terminal arbors outside the predicted
terminal zone (TZ) indicating that RGMa overexpression per-
turbed pathfinding. In contrary, no obvious axonal phenotype
was observed when H151A was overexpressed in the tectum
(Figure 3I). Here, 89% (8 of 9) of the embryos displayed normal
behavior with all fibers terminating their growth within the pre-
dicted TZ.
Together, these data demonstrate that RGMa catalytic pro-
cessing is required for interaction with Neogenin and the result-
ing neurite/axon growth inhibition.
C-RGMa on Its Own Is Sufficient for Neogenin Binding
and Growth Inhibition
It has been assumed that C-RGMa on its own is sufficient to
inhibit axonal growth (Rajagopalan et al., 2004). This notion
derives from experiments that were performed before the identi-
fication of a disulfide bridge between N- and C-RGMa (Tassew
et al., 2009), and remains to be tested. C-RGMa (33 kDa) is
poorly targeted to the cell surface when expressed on its own
(Tassew et al., 2009). Thus, to target C-RGMa to the cell surface,
we developed a construct (C-RGMaTEV) in which the original
autocatalytic cleavage site between N- and C-RGMa was
replaced by a TEV cleavage site (Phan et al., 2002; Figure 4A;
Figure S4). In ELISAs, either RGMawt or C-RGMaTEV membrane
preparations boundNeogenin-AP, but notably C-RGMaTEV (Kd =
6.8 nM) had a higher affinity than RGMawt (Kd = 11.96 nM;
Figures 4C–4E). These data suggested that C-RGMa may inhibit
axonal growth more effectively that the full-length protein.
Indeed, membranes containing C-RGMaTEV inhibited temporal
axons more potently than RGMawt (Figures 4F and 4G). As ex-
pected, outgrowth from nasal axons was significantly higher,
which is consistent with a role for Neogenin as the receptor (Fig-
ure 4G). To confirm that Neogenin mediated C-RGMa inhibition,ier Inc.
Figure 3. RGMa Cleavage Is Required for RGMa
Inhibition through Neogenin
(A) RGMa proteins tested.
(B) Expression of Neogenin-AP (Neo-AP) and RGMa
constructs in COS-7 and HEK293 cells. The introduction
of a single mutation (H151A, D149A) next to autocatalytic
cleavage site (aa 150) abolished cleavage in COS-7 cells.
The same mutations abolished all cleavage events in
HEK293 cells.
(C) Microtiter plates were coated with transfected COS-7-
membranes and Neogenin-AP binding studied. Binding is
abolished in noncleavable mutants (D149A, H151A)
versus wtRGMa (wt; see also Figures S3A–S3C).
(D) Temporal explants grown on Mock, wtRGMa (wt), and
noncleavable mutants (D149A; H151A) membranes.
Axonal growth is reduced on wtRGMa versus Mock and
mutants. Bar, 150 mm.
(E) In four independent experiments, mutation of the
cleavage site abolished RGMa inhibition on temporal
axons (**p < 0.05). Nasal axons that express less Neogenin
were less inhibited.
(F) NIE-115 cells were grown on Mock, wtRGMa (wt),
D149A, and H151A membranes, after transfection with
GFP plasmid plus a control shRNA (Ctrl-shRNA) or a
Neogenin shRNA (Neo-shRNA). NIE-115 cells transfected
with Ctrl-shRNA extend shorter neurites on wtRGMa
versus Mock, D149A, and H151A. Bar, 30 mm.
(G) D149A and H151A significantly increased length (**p <
0.001) compared to wtRGMa. Neogenin silencing with
Neo-shRNA suppressed wtRGMa inhibition. All data are
average ± SEM from three independent experiments (see
also Figure S3).
(H) Ectopic expression of RGMa induced axonal pheno-
types with numerous fibers establishing arbors outside the
Terminal Zone (TZ; arrowheads).
(I) Ectopic expression of H151A did not induce axonal
phenotypes and all axons established terminal arbors
within the TZ.
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C-RGMaTEV, RGMawt, and Mock-transfected membranes. In
agreement with retinal axon data, C-RGMaTEV and RGMawt
significantly hampered neurite growth, an effect that vanished
in the presence of Neogenin shRNA but not control shRNA
(Figures 4H and 4I).
To rule out the possibility that the activity in C-RGMaTEV
membranes resulted from unwashed N-RGMa fragments, we
sought to identify the C-RGMa domain that interacts with
Neogenin (Figure 4J). Using an interaction assay, we identified
a domain spanning aa residues 182–271 that is sufficient for
interaction with Neogenin (Figures 4J and 4K). In outgrowthDevelopmental Cell 22, 391experiments, C-RGMa182-271 strongly inhibited
temporal fibers (Figure S4B). A lesser effect
was obtained on nasal fibers suggesting that
this effect is mediated by Neogenin (Figure 4L).
To assess the function of C-RGMa182-271 on
retino-tectal map formation we performed its
ectopic expression in the chick tectum (Figures
S4B–S4E). In 90% (9 of 10) of the embryos,
C-RGMa182-271 expression resulted in aberrant
pathfinding (Figures 4M–4O). Together, these
data demonstrate that C-RGMa on its own issufficient for Neogenin interaction and inhibition of axonal
growth.
Three RGMa Soluble Proteins Inhibit Axonal Outgrowth
via Neogenin
Because RGMa is GPI anchored and has the same action on
growing fibers as ephrins (Drescher et al., 1997), it has been
assumed that only membrane-bound RGMa inhibits axons
(Monnier et al., 2002). To our knowledge, the release of three
soluble RGMa proteins (RGMaD, N-RGMa, and NN-RGMa;
Figure 1A) has not been reported before; we therefore sought
to determine their function using purified proteins on growing–402, February 14, 2012 ª2012 Elsevier Inc. 395
Figure 4. C-RGMa Induces Neogenin-Mediated Inhibition
(A) Representation of RGMa with a TEV site.
(B) Under nonreducing conditions, RGMa appears as a 60 kDa band, whereas RGMa-TEV is cleaved by TEV and only C-RGMa (33 kDa) is apparent.
(C and D) Neogenin-AP binds saturably to wtRGMa (C) and C-RGMa (D). Binding of Neogenin-AP or RGMa-AP to microtiter wells coated with C-RGMa and
wtRGMamembranes.Neogenin-APbinding toBSAwas less than 5%of these levels. CalculatedKdofNeogenin-AP is indicated. Data are fromsix determinations.
(E) Scatchard of Neogenin-AP binding (see also Figure S4).
(F) Temporal-axon growth was reduced on wtRGMa and C-RGMa membranes versus Mock. Bar, 150 mm.
(G) C-RGMa andwtRGMa significantly reduced length (**p < 0.001) of temporal axons. Nasal axonswere inhibited to a lesser extent. Data are average ±SEM from
four independent experiments.
(H) NIE-115 cells transfected with Ctrl-shRNA + GFP extend shorter neurites on C-RGMa versus Mock. Transfection of Neo-shRNA + GFP restored growth. Bar,
30 mm.
(I) C-RGMa andwtRGMa reduced NIE-115-neurite length (**p < 0.0001) in Ctrl-shRNA cells. Neo-shRNA suppressed this inhibition. Data are average ± SEM from
three independent experiments.
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Figure 5. Soluble RGMa Proteins Display Neoge-
nin-Dependent Inhibition
(A) RGMa proteins tested.
(B) Temporal explants on laminin, laminin+5 mg/ml N-
RGMa, 2.5 mg/ml NN-RGMa, and 10 mg/ml RGMaD. The
three RGMas inhibited growth. Bar, 200 mm.
(C) RGMa proteins significantly decreased growth (**p <
0.0001). Proteins displayed a concentration-dependent
effect, NN-RGMa having the strongest effect. Nasal axons
were less inhibited. Data are average ± SEM from four
independent experiments. Bar, 150 mm.
(D) NIE-115 cells on laminin, laminin+5 mg/ml NN-RGMa,
with control shRNA (Ctrl-shRNA)+GFP or a Neogenin
shRNA (Neo-shRNA) +GFP. Cells transfected with Ctrl-
shRNA extended shorter neurites on laminin+NN-RGMa,
compared to laminin. Neo-shRNA restored growth. Bar,
40 mm.
(E) RGMaD, N-RGMa, and NN-RGMa inhibited growth.
Neo-shRNA increased the average neurite-length on
N-RGMa, NN-RGMa, and RGMaD, when compared to
Ctrl-shRNA (**p < 0.05). Data are average ± SEM from four
independent experiments.
(F) Supernatants (Sup.) from cells transfected with N-
RGMa or NN-RGMa were pulled down (IP) by Neogenin-
but not BSA-coated beads.
(G–I) Neogenin-AP (2 mg/well) bound saturably to purified
RGMaD (G), N-RGMa (H), and NN-RGMa (I). RGMa-AP
(2 mg/well) did not bind to RGMa proteins. Neogenin-AP
binding to BSA was less than 5% of these levels. Kd of
Neogenin-AP is indicated.
(J) Scatchard plot of RGMa proteins binding.
Data are average ± SEM from four to eight determinations
(see also Figure S5).
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Proteolysis of RGMa Regulates Axonal Growthfibers (Figure S5). Strikingly, RGMaD, N-RGMa, and NN-RGMa
significantly inhibited retinal fibers in a concentration-dependent
manner (Figures 5B and 5C). All proteins restricted outgrowth
and displayed a greater activity on temporal versus nasal fibers,(J) Binding study of RGMas to Neogenin. RGMas were expressed as AP fusion proteins and teste
Neogenin (binding; , base line; ++, > 5 3 base line; +++, > 10 3 base line).
(K) Supernatants (Sup.) from cells transfected with C-RGMa182-271 were pulled down (IP) by Neogen
(L) C-RGMa182-271 reduced axonal length (**p < 0.005). Nasal axons were less inhibited. Data are av
(M–O) Ectopic expression of RGMa182-271 induced pathfinding errors in the visual pathway. In contro
(TZ), whereas in RGMa182-271 experiments fibers displayed aberrant paths (arrows) and connections
Developmental Cell 22, 391indicating that their receptor is present in higher
quantities on temporal fibers. Remarkably, the
shorter NN-RGMa fragment was the most
potent inhibitor of outgrowth as 1 mg/ml of this
protein led to 71% inhibition of temporal fibers,
similar to that obtained with 10 mg/ml of N-
RGMa (74%) or 20 mg/ml of RGMaD (72%;
Figure 5C).
Because all fragments displayed stronger
effect on temporal versus nasal axons, we
tested whether Neogenin mediates their inhibi-
tion. NIE-115 cells expressing a control shRNA
extended shorter processes on RGMaD, N-
RGMa, and NN-RGMa compared to laminin
alone, which was suppressed in cells express-
ing Neogenin-shRNA (Figures 5D and 5E).Here also, NN-RGMa (5 mg/ml) was more potent than N-RGMa
(10 mg/ml) and RGMaD (20 mg/ml; Figure 5E). Together with the
temporal/nasal difference described above (Figure 5C), these
data show that Neogenin mediates inhibition by N-RGMa,d in ELISA plates coated with the extracellular domain of
in- but not BSA-coated beads.
erage ± SEM from three independent experiments.
l experiments (M), all the fibers targeted the terminal zone
(arrow heads) outside the TZ (N and O).
–402, February 14, 2012 ª2012 Elsevier Inc. 397
Figure 6. Overexpression of Soluble RGMaProteins Perturbs Axonal
Pathfinding in the Embryonic Chicken Visual System
At embryonic day 1.5 (E1.5), RCAS-virus (control) and RCAS-RGMa (positive
control), RCAS-N-RGMa, and RCAS-NN-RGMa were injected into the devel-
oping optic tectum. At E15, a DiI crystal was placed in the temporal retina to
label fibers.
(A) In control experiments, all axons converge toward a well-defined terminal
zone (TZ).
(B–D) Infections with RGMa, N-RGMa, and NN-RGMa-expressing RCAS-
virus, induced (1) the absence of terminal zone, (2) the presence of ectopic
anterior terminations, (3) aberrant turns and ectopic posterior terminations. All
errors are indicated by arrow heads. The insets represent a drawing of the flat-
mounted retina to indicate the location of the DiI crystal in a dorsotemporal
position of the retina and the path of axons toward the optic fissure. t,
temporal; d, dorsal; v, ventral; n, nasal. The hypothetical TZ is represented in
each panel (see also Figure S6).
(E) Quantification of axonal phenotypes. -TZ, no terminal zone; AT, ectopic
anterior terminations; PT, ectopic posterior terminations; Ab, aberrant turns.
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Proteolysis of RGMa Regulates Axonal GrowthNN-RGMa, and RGMaD (Figures 5D and 5E). Unexpectedly, this
revealed that, unlike ephrins, soluble RGMa proteins inhibit
axonal growth.
RGMa Soluble Proteins Display Various Affinities
to Neogenin
These data prompted us to examine whether Neogenin interacts
directly with soluble N-terminal RGMa proteins. We performed
pull down on supernatants from cells expressing N-RGMa or
NN-RGMa, and observed coimmunoprecipitation with Neoge-
nin- but not BSA-coated beads (Figure 5F), raising the possibility
that they directly interact with Neogenin. Because RGMa
proteins displayed varying potency, we determined binding
affinities to Neogenin (Figures 5G–5J). Purified RGMaD bound398 Developmental Cell 22, 391–402, February 14, 2012 ª2012 Elsevto Neogenin-AP with a Kd of 16.9 nM (Figure 5G). The interaction
was specific because RGMa-AP did not bind detectably to
RGMa fragments and Neogenin-AP did not bind to BSA-coated
wells. In the same assay, N-RGMa exhibited a higher affinity to
Neogenin-AP with a calculated Kd of 11.8 nM (Figure 5H). Strik-
ingly, the affinity of Neogenin for NN-RGMa was substantially
greater with a Kd of 1.5 nM, 11-fold greater than the soluble
full-length RGMaD protein (Figures 5I and 5J). A similar study
in which NN-RGMa-AP and N-RGMa-AP interact with Neoge-
nin-coated plates was performed and confirmed NN-RGMa’s
higher affinity (Kd = 1.2 nM) for Neogenin compared to N-
RGMa (Kd = 8.2 nM; Figure S5). These affinities correlate with
the inhibitory action of RGMa proteins on outgrowth (Figure 5C).
N-RGMa and NN-RGMa Perturb Pathfinding In Vivo
RGMa gain- and loss-of-function experiments indicate that it is
a key protein for the establishment of visual maps (Matsunaga
et al., 2006). However, these experiments did not establish which
RGMa fragment(s) is (are) involved in pathfinding. The fact that
secreted RGMa proteins may control retinal axon pathfinding
was unexpected as RGMa was believed to (1) function similar
to ephrins, which require polymerization in membranes to guide
axons (Egea and Klein, 2007) and (2) use its C-terminal portion to
inhibit axonal growth. To assess a role of N-RGMa, and NN-
RGMa during retinal-map formation, we performed ectopic
expression of these proteins in the developing tectum using
viral-mediated expression (Figure S6). In controls (empty virus),
retinal fibers directly targeted the predicted terminal zone (TZ;
Figure 6A). However, when N-RGMa and NN-RGMa were over-
expressed (Figure 5) pathfinding was greatly perturbed (Figures
6B–6D). Abnormal axonal paths included terminations outside
the TZ, aberrant turns within the optic tectum, as well as the
absence of a clear TZ (Figures 6B–6D). In situ hybridization has
demonstrated that expression patterns of other guidance mole-
cules are not affected by ectopic expression of RGMa (Matsu-
naga et al., 2006), thus, the axon-targeting phenotype arises
from an effect of overexpression of RGMa constructs and not
from a modification of other proteins. In summary, ectopic
expression of soluble RGMa N-terminal proteins indicates that
they are involved in the formation of visual maps.
C- and N-RGMa Proteins Interact with the Same
Neogenin FNIII(3-4) Domain
We next sought to identify the Neogenin domain(s) with which
C- and N-RGMa proteins interact. The extracellular portion of
Neogenin contains four Immunoglobulin like (4Ig) and six Fibro-
nectin type III (6FNIII) domains (Figure 7A). It has been reported
that 6FNIII interacts with full-length RGMa (Rajagopalan et al.,
2004). Using 6FNIII-AP, we showed that C- and N-RGMa
proteins interact with 6FNIII (Figure 7A). Next, we sought to iden-
tify which sub-region of the 6FNIII domain(s) interact with N- and
C-RGMa. To do so, we generated Neogenin constructs that
contain only some of the six FNIII domains (Figure 7A). In interac-
tion assays, the FNIII (2-5) domains bound to all C- and N-RGMa
proteins, which contrasted with domains 1–3 and 4–6 that did
not interact with any RGMa protein (Figure 7A). To further refine
the location of the binding motif, we generated a construct that
only contains the FNIII(3-4) domains, and showed that this
segment was sufficient for binding to each one of the RGMaier Inc.
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Figure 7. N- and C-RGMa Inhibit Axonal Outgrowth by Binding to the Same Neogenin Domain
(A) The extracellular portion of Neogenin consists of four immunoglobulin-like (4Ig) and six fibronectin type III (6FNIII) domains. ELISA plates were coated with
RGMa proteins and binding of Neogenin-AP was studied. (Binding; , base line; + > 2 3 base line; ++ > 3 3 base line; +++ > 5 3 base line). The three to four
fibronectin (FNIII[3-4]) domains sufficed for binding to RGMa proteins.
(B) ELISA plates were coated with N-RGMa or C-RGMa and binding of 6FNIII-AP was assessed after incubation with C-RGMa182-271, N-RGMa or NN-RGMa.
Preincubation with either N- or C-RGMa proteins altered 6FNIII-AP binding to both C- and N-RGMa proteins.
(C) Temporal axons grown on combinations of N- and C-RGMa.
(D) Quantification of axonal growth on 5 mg/ml of N-RGMa, 5 mg/ml C-RGMa182-271, and 2.5 mg/ml N-RGMa + 2.5 mg/ml C-RGMa182-271 (**p < 0.005). Data are
average ± SEM from three independent experiments.
(E) Temporal axons grown on N- and C-RGMa in the presence or absence of FNIII(3-4).
(F) Quantification of axonal growth on laminin, laminin + 2.5 mg/ml of N-RGMa, and laminin + 2.5 mg/ml C-RGMa182-271 in the presence or absence of FNIII(3-4).
FNIII(3-4) significantly restored axonal growth on N-RGMa, and C-RGMa182-271 (**p < 0.01). Data are average ± SEM from three independent experiments.
(G) Model for RGMa action on Neogenin. SKI-1 and Furin digest RGMa into C- and N-terminal proteins all interact with the fibronectin domain (3-4) of Neogenin
(red) to inhibit axonal growth.
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Proteolysis of RGMa Regulates Axonal Growthproteins (Figure 7A). Because C- and N-RGMa fragments bind to
the same Neogenin subdomain, we tested whether they interfere
with each other. In these experiments, we assessed 6FNIII-AP
binding to C- or N-RGMa after incubation with either one of these
proteins. As expected, preincubation of Neogenin with C-RGMa
abolished binding to C-RGMa. Interestingly, preincubation with
N-RGMa also inhibited binding of Neogenin to C-RGMa, indi-
cating that C- and N-RGMa interfere in their binding to Neogenin
(Figure 7B). In agreement with these data, binding to N-RGMa
was also altered when Neogenin was preincubated to either
C- or N-terminal fragments (Figure 7B). Next we studied the
effect of the combined presence of RGMa proteins on axonal
growth. When axons were grown on equimolar concentrations
of either N-RGMa (5 mg/ml), C-RGMa182-271 (5 mg/ml, these
proteins have the same apparent molecular weight) or N-
RGMa (2.5 mg/ml) + of C-RGMa182-271 (2.5 mg/ml), all treatments
resulted in inhibitions that did not significantly differ from each
other (Figures 7C and 7D). This represents the third indication
that both N- and C-fragments act through FNIII(3-4).
To further assess the role of FNIII(3-4) in RGMa inhibition, we
tested its function-blocking capability. Retinal axons were grown
on RGMa proteins in the presence of 1 mg/ml of FNIII(3-4).
Remarkably, the presence of this fragment restored axonal
growth on RGMaD, N-RGMa, and C-RGMa, indicating that it
blocked the inhibitory activities of these proteins on retinal axons
(Figures 7E and 7F). Together, these data represent a unique
example in which two unrelated domains of a same guidance
molecule inhibit axonal growth through interaction with the
same receptor region.
DISCUSSION
RGMa has critical roles in axonal growth, cell differentiation,
apoptosis, neuronal regeneration, and bone development (Mon-
nier et al., 2002; Matsunaga et al., 2004, 2006; Hata et al., 2006;
Zhou et al., 2010). Our data revealed that proteolytic cleavage
together with the formation of a disulfide bridge generate 4
membrane-bound and three soluble RGMa species. This level
of complexity was not expected as it was believed that only
full-length RGMa, in which RGMa is either uncleaved or its N-
and C-RGMa fragments remain attached by a disulfide bridge,
is expressed in vivo (Tassew et al., 2009). We studied the activity
of individual RGMa proteins and showed that all cleaved protein
products inhibit neurite growth via Neogenin, while the full-length
uncleaved membrane-bound RGMa is inactive. Hence, proteol-
ysis is required for RGMa activity. Furthermore, we show that
two Proprotein Convertases (PCs), namely Furin and SKI-1 are
involved in RGMa processing and generate N-terminal soluble
and C-terminal membrane-bound proteins with different inhibi-
tory activities. Surprisingly, RGMa fragments with no apparent
sequence homology all interacted with the same Fibronectin
domains in Neogenin to inhibit axonal growth.
Regulation of the activity of extracellular proteins by proteo-
lytic cleavage is an emerging theme within the CNS (Adams
et al., 1997). PCs form a family of nine proteinases with a large
array of functions within the CNS (Seidah and Chre´tien, 1999).
Somemembers of the family have been shown to process extra-
cellular proteins thereby regulating axonal growth. For instance,
Furin activates members of the Semaphorin family (Adams et al.,400 Developmental Cell 22, 391–402, February 14, 2012 ª2012 Elsev1997). Similarly, PC5/6A cleaves the neural adhesion molecule
L1, an event that appears important for L1-dependent neurite
growth of cerebellar neurons (Kalus et al., 2003). Thus far,
SKI-1 has not been shown to play any role within theCNS. There-
fore, this study uncovers an unexpected aspect of SKI-1 function
in the CNS. SKI-1 knockout mice die at embryonic days 2–3
(Mitchell et al., 2001) and that of Furin die of heart defect at
embryonic day 11 (Roebroek et al., 1998). Thus, a function for
these proteins could not be assessed within the developing
CNS. Using local perturbation of SKI-1 and Furin function in
the developing tectum, we generated evidence that both
proteins regulate axonal growth in vivo.
RGMa and ephrin-A5,-A2 are GPI-anchored proteins that
guide retinal fibers (Monnier et al., 2002; Drescher et al., 1997).
Thus, they have both been assumed to function as membrane-
bound cues. Here, however, we show that soluble RGMa
proteins also strongly inhibit fiber growth. This is in stark contrast
to ephrins, which require oligomerization in membrane clusters
to be functionally active (Egea and Klein, 2007). Activity of eph-
rins is also regulated by proteolytic processing. For instance,
ephrin-A2 is cleaved by Kuzbanian after binding to its receptor,
a mechanism that leads to axon detachment and termination
of signaling (Hattori et al., 2000). Strikingly, release of RGMa
from the membrane has the opposite effect since uncleaved
membrane-bound protein is inactive, and proteolysis creates
active soluble RGMa proteins. Thus, our data invoke an unex-
pected mechanism of action for RGMa in which the combination
of long (soluble) and short (membrane-bound) range guidance
regulates topographic mapping.
Surprisingly, unrelated N- and C-terminal fragments inhibit
axonal growth via the same Fibronectin domains in Neogenin.
At first sight this result confirms a recent study in which we
showed that both domains are involved in retino-tectal path-
finding (Tassew et al., 2009). Because in COS-7 cells, N- and
C-RGMa are linked to each other by a disulfide bridge, the logical
interpretation was that RGMa simultaneously requires N- and
C-RGMa for interaction with Neogenin. We now postulate that
pathfinding toward the optic tectum can be controlled by inde-
pendent and unrelated N- and C-terminal RGMa fragments. It
is known for other proteins such as Nogo or NG2 that multiple
distinct regionsmight contribute to their inhibitory activity (Oertle
et al., 2003). However, unlike RGMa, each one of these regions
uses a distinct receptor to transmit its inhibitory activities (Oertle
et al., 2003). Ephrins have two domains that interact with the
Eph receptors; however, only one of these domains has an
inhibitory action on growing fibers (Carvalho et al., 2006). Slit2
is processed into several peptides, however only the D2 inhibi-
tory domain binds to robo-receptor whereas the other inhibitory
domain D4 interacts with heparin sulfate (Seiradake et al., 2009).
Thus, to our knowledge, RGMa represents the first example in
which multiple inhibitory fragments from a single ligand regulate
axonal growth through the same receptor domain.
As well as controlling connections within the developing
CNS, RGMa is involved in neurodegenerative diseases. Thus,
it is a major impediment to neuronal regeneration and anti-
bodies that neutralize C-RGMa promote regeneration (Hata
et al., 2006). Moreover, there is growing evidence that RGMa
is a key player in multiple sclerosis (Muramatsu et al., 2011;
Nohra et al., 2010). In the light of our new data, multipleier Inc.
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Proteolysis of RGMa Regulates Axonal GrowthRGMa-fragments may contribute to the negative environment
that hampers regeneration following CNS injury. Optimal
approaches to deactivate RGMa should target all inhibitory
C- and N-terminal fragments. The RGM family is implicated
in the disease hemochromatosis (Papanikolaou et al., 2004),
and accordingly it will be important to determine whether the
complex processing we uncovered here affects the activity of
other RGM proteins.
EXPERIMENTAL PROCEDURES
Cloning, Expression, and Purification
All RGMa constructs were cloned in pSectag2B vector (Invitrogen) with an
N-terminal His-tag. They were then transferred to RCAS BP(B) vector for viral
production. SKI-1 and ppFurin were cloned in the bicistronic eGFP-containing
pIRES vector (Invitrogen) as we published before (Pullikotil et al., 2004).
C-RGMa-TEV was cloned by inserting a TEV cleavage site between
N-RGMa and C-RGMa. Membranes were prepared from transfected cells,
washed and resuspended in 13 TEV buffer and cleaved with AcTEV protease
(Invitrogen) ON at 4C. Membranes were washed to remove the cleaved
N-terminal part, and resuspended in PBS.
Soluble proteins were purified using Ni-NTA agarose (Invitrogen) and dia-
lyzed in PBS. Anti-His (QIAGEN) and anti-RGMa (8B6; Tassew et al., 2009)
were used.
Binding Assay
A 96-well plate was coated with (1) poly-L-lysine (100 ml, 10 mg/ml) and (2)
membrane suspensions (100 ml) adjusted to an OD of 0.1 (at 220 nm) were
added to the wells. Plates were then centrifuged at 3,000 rpm (15 min at
4C), blocked with 5%BSA for 1 hr, and different concentrations of AP-tagged
proteins were added for 3 hr. Wells were washed with PBS, incubated at 65C
for 1 hr to deactivate endogenous AP and developed with 1 mg/ml pNPP.
For binding assay, wells were coated with purified proteins (3 hr at room
temperature [RT]), and blocked with 5% BSA (1 hr), followed by incubation
with AP-tagged proteins (2 mg/well; 3 hr at RT). To quantify the binding, absor-
bance at 405 nm was measured by using a microplate reader (EL 311SX,
Bio-TEK Instruments Inc.). Kd and scatchard plots were obtained after fitting
the data using a nonlinear curve fit by GraphPad Prism 5 software.
Neogenin Silencing and Neurite Outgrowth
Mouse Neogenin shRNA and control shRNA were gifts from Dr. Yamashita T.
NIE-115 cells which endogenously express Neogenin were cotransfected with
shRNA and GFP. Twenty-four hours later, cells were plated on coverslips
coated with membranes from Mock, wtRGMa, D149A and H151A (OD of 0.1
at 220 nm). Alternatively, cells were cultured on molar equivalent amounts of
soluble proteins, RGMaD (20 mg/ml), N-RGMa (10 mg/ml) and NN-RGMa
(5 mg/ml). Cells were differentiated in 2% DMSO and neurite length was
measured 48 hr later.
Retinal Explants Outgrowth Assay
Glass coverslips were coated with 10 mg/ml poly-L-lysine, treated with laminin
(10 mg/ml), and membrane preparations from transfected cells were added
and centrifuged for 15 min at 3,000 3 g and 4C. Alternatively, different
concentrations of soluble proteins mixed with laminin (10 mg/ml) were added
to the coverslips and incubated for 3 hr at RT. Explants from the temporal
and Nasal retina were then added to either membrane-or protein-coated
surfaces in DMEM F-12 media (2% chick serum, 10% FBS) and incubated
(37C, 5% CO2) for 18 hr. Explants were fixed in 4%PFA, permeablized with
0.1% Triton X-100, stained with Alexa488-fluor-phalloidin and viewed under
a fluorescence microscope (Zeiss). The number and length of fibers were
then quantified using Image Pro 5.0. Only explants which displayed growth
were considered.
Cell Treatments
HEK cells transfected with RGMa and grown for 24 hr were treated with 50 mM
RVKR, 300 mM AEBSF (ENZO life science), and 50 mM RRLL (BACHEM) for
12 hr before membranes or supernatants were processed.DevelopmPull-Down Assay
Proteins were coupled to activated-CNBr Sepharose (Pharmacia). Beadswere
then blocked with 100 mM Tris-HCl, (pH 8) and washed. Supernatants from
transfected cells were added to coupled beads for 2 hr at RT. Beads were
then washed six times with PBS +0.02% Tween 20, and SDS loading buffer
was added. Samples were boiled and subjected to western blotting.
Preparation of Viral Stocks
DF1 cells (DSHB) were transfected with RCAS constructs using lipofectamine
2000 (Invitrogen). Cultures were expanded and supernatants were collected,
pooled, and concentrated by centrifugation (21,000 rpm, 2 hr) in a SW 28
rotor (Beckman). Viral titer was determined by infecting DF1 cells with
serial dilutions and staining for the gag protein (AMV-3C2 Ab; DSHB). Titers
of 1 3 108 IU/ml were used for infections.
In Ovo Injection and DiI Tracing
Eggs (White Leghorn) were incubated at 38C in high-humidity. At E1.5 viral
solution (viral titers of 13 108 IU/ml) was injected in the tectum. At E15, a small
DiI crystal (Molecular Probes) was placed in the temporodorsal part of the
right eye. At E17, tecta were fixed in 4% PFA. DiI tracing was viewed under
a fluorescent microscope (Olympus BX61) after cutting the tecta in half. Digital
Images were taken and processed using Photoshop (Adobe).
Statistical Analysis
Quantifications were done for binding and outgrowth assays from at least
three independent experiments. Statistical analysis was performed using
ANOVA by XLSTAT. Results are expressed as the average ± SEM.
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